MARKET

ARNA

ARNA

Arena Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

73.69
+0.65
+0.89%
After Hours: 73.69 0 0.00% 16:32 09/25 EDT
OPEN
73.20
PREV CLOSE
73.04
HIGH
74.64
LOW
72.97
VOLUME
685.93K
TURNOVER
--
52 WEEK HIGH
74.64
52 WEEK LOW
32.95
MARKET CAP
4.25B
P/E (TTM)
-10.7925
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 2d ago
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
Benzinga · 3d ago
Arena Pharmaceuticals to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Wednesday, September 23, at 1:45 PM ET.
PR Newswire · 09/18 14:00
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 09/17 11:59
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in the ELEVATE UC 12 global Phase 3 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment
PR Newswire · 09/16 12:30
Arena Pharmaceuticals (ARNA) Investor Presentation - Slideshow
The following slide deck was published by Arena Pharmaceuticals, Inc. in conjunction with this event.
Seekingalpha · 09/11 21:39
How Much is Arena Pharmaceuticals' (NASDAQ:ARNA) CEO Getting Paid?
Amit Munshi became the CEO of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in 2016, and we think it's a good time to look...
Simply Wall St. · 09/11 14:59
Hedge Funds Aren’t Done Buying Arena Pharmaceuticals, Inc. (ARNA)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
Insider Monkey · 09/09 14:40
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ARNA. Analyze the recent business situations of Arena Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ARNA stock price target is 86.08 with a high estimate of 120.00 and a low estimate of 70.00.
EPS
Institutional Holdings
Institutions: 352
Institutional Holdings: 56.80M
% Owned: 98.54%
Shares Outstanding: 57.65M
TypeInstitutionsShares
Increased
80
9.59M
New
89
3.64M
Decreased
74
4.44M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Tina Nova
President/Chief Executive Officer/Director
Amit Munshi
Chief Financial Officer/Executive Vice President
Laurie Stelzer
Executive Vice President/General Counsel/Secretary
Joan Schmidt
Executive Vice President
Vincent Aurentz
Executive Vice President
Robert Lisicki
Director
Katharine Knobil
Independent Director
Jayson Dallas
Independent Director
Oliver Fetzer
Independent Director
Kieran Gallahue
Independent Director
Jennifer Jarrett
Independent Director
Garry Neil
Independent Director
Manmeet Soni
Independent Director
Randall Woods
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ARNA
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Arena Pharmaceuticals, Inc. stock information, including NASDAQ:ARNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARNA stock methods without spending real money on the virtual paper trading platform.